Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Add filters

Year range
Small Sci ; : 2100124, 2022 Mar 13.
Article in English | MEDLINE | ID: covidwho-1739237


The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an enormous threat to public health. The SARS-CoV-2 3C-like protease (3CLpro), which is critical for viral replication and transcription, has been recognized as an ideal drug target. Herein, it is identified that three herbal compounds, Salvianolic acid A (SAA), (-)-Epigallocatechin gallate (EGCG), and Oridonin, directly inhibit the activity of SARS-CoV-2 3CLpro. Further, blocking SARS-CoV-2 infectivity by Oridonin is confirmed in cell-based experiments. By solving the crystal structure of 3CLpro in complex with Oridonin and comparing it to that of other ligands with 3CLpro, it is identified that Oridonin binds at the 3CLpro catalytic site by forming a C-S covalent bond, which is confirmed by mass spectrometry and kinetic study, blocking substrate binding through a nonpeptidomimetic covalent binding mode. Thus, Oridonin is a novel candidate to develop a new antiviral treatment for COVID-19.

Evid Based Complement Alternat Med ; 2021: 4303380, 2021.
Article in English | MEDLINE | ID: covidwho-1455773


BACKGROUND: In view of the global efforts to develop effective treatments for the current worldwide coronavirus 2019 (COVID-19) pandemic, Qingfei Paidu decoction (QPD), a novel traditional Chinese medicine (TCM) prescription, was formulated as an optimized combination of constituents of classic prescriptions used to treat numerous febrile and respiratory-related diseases. This prescription has been used to treat patients with COVID-19 pneumonia in Wuhan, China. Hypothesis/Purpose. We hypothesized that QPD would have beneficial effects on patients with COVID-19. We aimed to prove this hypothesis by evaluating the efficacy of QPD in patients with COVID-19 pneumonia. METHODS: In this single-center, retrospective, observational study, we identified eligible participants who received a laboratory diagnosis of COVID-19 between January 15 and March 15, 2020, in the west campus of Union Hospital in Wuhan, China. QPD was supplied as an oral liquid packaged in 200-mL containers, and patients were orally administered one package twice daily 40 minutes after a meal. The primary outcome was death, which was compared between patients who did and did not receive QPD (QPD and NoQPD groups, respectively). Propensity score matching (PSM) was used to identify cohorts. RESULTS: In total, 239 and 522 participants were enrolled in the QPD and NoQPD groups, respectively. After PSM at a 1 : 1 ratio, 446 patients meeting the criteria were included in the analysis with 223 in each arm. In the QPD and NoQPD groups, 7 (3.2%) and 29 (13.0%) patients died, and those in the QPD group had a significantly lower risk of death (hazard ratio (HR) 0.29, 95% CI: 0.13-0.67) than those in the NoQPD group (p = 0.004). Furthermore, the survival time was significantly longer in the QPD group than in the NoQPD group (p < 0.001). CONCLUSION: The use of QPD may reduce the risk of death in patients with COVID-19 pneumonia.

SciFinder; 2020.
Preprint | SciFinder | ID: ppcovidwho-4443


A review. The prognosis of novel coronavirus pneumonia (COVID-19) is closely related to host′s immune response. Immunity system plays a vital role in controlling and eliminating virus infections. Thymosin immunomodulators can enhance the body′s cellular immune function. Based on existing evidences, this paper reviews the sources and differences of thymosin drugs, of which the immunomodulatory effects in different populations and application in viral infection are also summarized. In addition, we discuss the roles of thymosin drugs in the prevention and treatment of new coronavirus infections, and put forward suggestions for drug selection and pharmaceutical care, in order to provide reference for clin. decision-making related to new coronavirus pneumonia and improve its prevention and treatment effects.

SciFinder; 2020.
Preprint | SciFinder | ID: ppcovidwho-3575


A review. At present, the diagnosis and treatment of corona virus disease 2019 (COVID-19) has entered a critical period. The treatment of complex and changeable disease requires the cooperation of doctors, nurses and pharmacists. Therefore, from the perspective of pharmaceutical service, this article introduced some important aspects to improve the treatment of COVID-19, including the formulation of pharmaceutical care standards, prescription and medical order review, remote pharmaceutical care for COVID-19, pharmaceutical care for COVID-19 patients in the hospital and science popularization of COVID-19. As an important part of the prevention and control of epidemic disease, clin. pharmacy service has played an active role in ensuring the safety and effectiveness of patients′ medication, thereby making contribution to the effective control of the epidemic.